Markus Dold

3.6k total citations
67 papers, 2.2k citations indexed

About

Markus Dold is a scholar working on Pharmacology, Psychiatry and Mental health and Experimental and Cognitive Psychology. According to data from OpenAlex, Markus Dold has authored 67 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pharmacology, 32 papers in Psychiatry and Mental health and 21 papers in Experimental and Cognitive Psychology. Recurrent topics in Markus Dold's work include Treatment of Major Depression (41 papers), Tryptophan and brain disorders (20 papers) and Bipolar Disorder and Treatment (18 papers). Markus Dold is often cited by papers focused on Treatment of Major Depression (41 papers), Tryptophan and brain disorders (20 papers) and Bipolar Disorder and Treatment (18 papers). Markus Dold collaborates with scholars based in Austria, United Kingdom and Italy. Markus Dold's co-authors include Stefan Leucht, Siegfried Kasper, Lucie Bartova, Werner Kissling, Alessandro Serretti, Daniel Souery, Stuart Montgomery, Julien Mendlewicz, John M. Davis and Joseph Zohar and has published in prestigious journals such as Cochrane Database of Systematic Reviews, Pharmacological Reviews and The British Journal of Psychiatry.

In The Last Decade

Markus Dold

63 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markus Dold Austria 24 970 823 571 498 403 67 2.2k
Florian Seemüller Germany 30 1.5k 1.6× 673 0.8× 515 0.9× 304 0.6× 547 1.4× 99 2.5k
Carla M. Canuso United States 26 1.5k 1.5× 1.1k 1.4× 342 0.6× 653 1.3× 463 1.1× 76 2.8k
Tom Bschor Germany 35 1.9k 2.0× 1.1k 1.4× 603 1.1× 563 1.1× 512 1.3× 136 3.6k
Won‐Myong Bahk South Korea 28 1.7k 1.7× 600 0.7× 327 0.6× 439 0.9× 555 1.4× 214 3.0k
Stefano Porcelli Italy 24 750 0.8× 603 0.7× 358 0.6× 417 0.8× 396 1.0× 72 2.0k
Ajeet Singh Australia 25 1.2k 1.2× 727 0.9× 283 0.5× 406 0.8× 443 1.1× 73 2.6k
Kiyomi Shinohara Japan 17 755 0.8× 1.3k 1.6× 930 1.6× 693 1.4× 656 1.6× 26 3.4k
Hans Eriksson United States 25 1.2k 1.3× 1.1k 1.3× 562 1.0× 205 0.4× 360 0.9× 71 2.2k
J. Craig Nelson United States 33 1.4k 1.5× 1.3k 1.6× 613 1.1× 476 1.0× 496 1.2× 87 3.2k
Timothy Petersen United States 31 910 0.9× 1.2k 1.4× 716 1.3× 501 1.0× 647 1.6× 68 2.7k

Countries citing papers authored by Markus Dold

Since Specialization
Citations

This map shows the geographic impact of Markus Dold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Dold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Dold more than expected).

Fields of papers citing papers by Markus Dold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Dold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Dold. The network helps show where Markus Dold may publish in the future.

Co-authorship network of co-authors of Markus Dold

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Dold. A scholar is included among the top collaborators of Markus Dold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Dold. Markus Dold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dold, Markus, Hans‐Jürgen Möller, Hans‐Peter Volz, et al.. (2024). Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials. European Psychiatry. 67(1). e23–e23. 3 indexed citations
2.
3.
Kautzky, Alexander, Lucie Bartova, Gernot Fugger, et al.. (2023). Age as a moderating factor of treatment resistance in depression. European Psychiatry. 66(1). e35–e35. 4 indexed citations
4.
Bartova, Lucie, Markus Dold, Hans‐Peter Volz, et al.. (2022). Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. European Archives of Psychiatry and Clinical Neuroscience. 273(1). 51–63. 11 indexed citations
5.
Fugger, Gernot, Lucie Bartova, Chiara Fabbri, et al.. (2022). The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. Journal of Affective Disorders. 312. 225–234. 3 indexed citations
6.
Bartova, Lucie, Gernot Fugger, Markus Dold, et al.. (2021). The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder. The International Journal of Neuropsychopharmacology. 25(2). 118–127. 2 indexed citations
7.
Dold, Markus, Lucie Bartova, Gernot Fugger, et al.. (2021). Melancholic features in major depression – a European multicenter study. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 110. 110285–110285. 22 indexed citations
8.
Bartova, Lucie, Markus Dold, Gernot Fugger, et al.. (2021). Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. Depression and Anxiety. 38(9). 896–906. 20 indexed citations
9.
Kautzky, Alexander, Markus Dold, Lucie Bartova, et al.. (2020). Combining machine learning algorithms for prediction of antidepressant treatment response. Acta Psychiatrica Scandinavica. 143(1). 36–49. 33 indexed citations
10.
Dold, Markus & Siegfried Kasper. (2020). Dose‐response relationship of selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica. 142(6). 427–429. 1 indexed citations
11.
Dold, Markus, Lucie Bartova, & Siegfried Kasper. (2020). Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment. The International Journal of Neuropsychopharmacology. 23(7). 440–445. 20 indexed citations
12.
Fugger, Gernot, Markus Dold, Lucie Bartova, et al.. (2019). Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study. European Neuropsychopharmacology. 29(6). 777–785. 23 indexed citations
13.
Bartova, Lucie, Markus Dold, Alexander Kautzky, et al.. (2019). Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice. The World Journal of Biological Psychiatry. 20(6). 427–448. 93 indexed citations
14.
Kautzky, Alexander, Markus Dold, Lucie Bartova, et al.. (2018). Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatrica Scandinavica. 139(1). 78–88. 99 indexed citations
15.
Dold, Markus, Lucie Bartova, Gernot Fugger, et al.. (2018). Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). The International Journal of Neuropsychopharmacology. 21(6). 539–549. 67 indexed citations
16.
Dold, Markus, Lucie Bartova, Daniel Souery, et al.. (2018). Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. Acta Psychiatrica Scandinavica. 137(5). 401–412. 31 indexed citations
17.
Fugger, Gernot, Markus Dold, Lucie Bartova, et al.. (2018). Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). European Neuropsychopharmacology. 28(6). 752–760. 51 indexed citations
18.
Kautzky, Alexander, Markus Dold, Lucie Bartova, et al.. (2017). Refining Prediction in Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 79(1). 16m11385–16m11385. 58 indexed citations
19.
Leucht, Stefan, et al.. (2012). Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. The British Journal of Psychiatry. 200(2). 97–106. 230 indexed citations
20.
Dold, Markus, et al.. (2012). Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews. 2012(11). CD006391–CD006391. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florian Seemüller Breakdown of academic impact, for papers by Carla M. Canuso Breakdown of academic impact, for papers by Tom Bschor Breakdown of academic impact, for papers by Won‐Myong Bahk Breakdown of academic impact, for papers by Stefano Porcelli Breakdown of academic impact, for papers by Ajeet Singh Breakdown of academic impact, for papers by Kiyomi Shinohara Breakdown of academic impact, for papers by Hans Eriksson Breakdown of academic impact, for papers by J. Craig Nelson Breakdown of academic impact, for papers by Timothy Petersen
Rankless by CCL
2026